product name Betamethasone
Description: Betamethasone (also called NSC-39470, SCH-4831) is a glucocorticoid steroid with anti-inflammatory and immunosuppressive properties. Betamethasone has shown the inflammatory response by the betamethasone-receptor complex modulated the activity of certain genes, altering the production and activity of proteins. Betamethasone has been reported to inhibit the expression of these enzymes results in reduced production of such inflammatory mediators as prostaglandins, leukotrienes and nitric oxide.
References: J Physiol. 2000 Nov 1;528(Pt 3):619-32; Ann Clin Lab Sci. 2006 Winter;36(1):39-46.
392.46
Formula
C22H29FO5
CAS No.
378-44-9
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 79 mg/mL (201.3 mM)
Water: <1 mg/mL
Ethanol: 10 mg/mL (25.5 mM)
Solubility (In vivo)
Synonyms
NSC-39470, SCH-4831
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19422821
| In Vitro |
In vitro activity: Betamethasone has a specific affinity for type II glucocorticoid receptors which are present in most brain regions. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Betamethasone has direct vasoconstrictor effects on peripheral femoral resistance vessels in late gestation fetal sheep. Betamethasone exposure decreases cerebral blood flow (CBF) in all brain regions measured except the hippocampus after 24 hours of infusion in sheep. Betamethasone reduces the activation of NF-kappaB and elevation of TNFalpha and IL-1beta, and induces the expression of IL-10 in the brain, all of which correlate with the changes of pain thresholds in rats. Betamethasone exposure reduces synaptophysin-LI in the frontal neocortex, caudate putamen and hippocampus by 46.9%, 41.0% and 55.4%, respectively, that is not accompanied by irreversible neuronal damage in the fetal sheep brain. Betamethasone modestly increases cytidylyltransferase (CT) mRNA, but does not alter the levels of immunoreactive enzyme in adult rat lung. Betamethasone decreases the activities of the sphingomyelin hydrolases: acid sphingomyelinase by 33% and of alkaline ceramidase by 21%. Betamethasone injected at the time of nerve injury partially inhibits the development of neuropathic hyperalgesia and reduces the subsequent elevated levels of pro-inflammatory cytokines in the brain of rats, while stimulating the expression of the anti-inflammatory cytokine IL-10. |
| Animal model | |
| Formulation & Dosage | |
| References | J Physiol. 2000 Nov 1;528(Pt 3):619-32; Ann Clin Lab Sci. 2006 Winter;36(1):39-46. |
